Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 4 1Phase 3 1Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 2CNS 2Thoracic 1Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1

Conditions

Endobronchial Metastases 1

Interventions

Oxaliplatin 21Capecitabine 19Fluorouracil 16Bevacizumab 16Esomeprazole 11Sorafenib 10Irinotecan 9Leucovorin 8Radiofrequency Ablation 7Propofol 7Bismuth 7Morphine 6Gemcitabine 6Folfox protocol 6Amoxicillin 6lenvatinib 5gadolinium ethoxybenzyl DTPA 5Tetracycline 5Sevoflurane 5S 1 (combination) 5Drug Therapy 5Control Groups 5Cisplatin 5sodium glycididazole 4fish oil triglycerides 4ferric carboxymaltose 4Sodium Chloride 4Ropivacaine 4Ribavirin 4Hepatectomy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Sugammadex × Gastrointestinal × Clear all
NCT05468671 2022-10-26

Clinical Application Value of Remazolam Combined With Sugammadex Sodium in Anesthesia for Endotracheal Surgery Under Bronchoscopy

Zhejiang Cancer Hospital

Phase 4 Completed
34 enrolled
GastrointestinalThoracic

Endobronchial Metastases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡